Estudio de polimorfismos de la Óxido Nítrico Sintasa Endotelial (NOSE) en pacientes con lupus eritematoso sistémico

Vista sencilla de ítem
dc.contributor.advisorDíaz Martínez, Luis Alfonso
dc.contributor.authorSerrano Díaz, Norma Cecilia
dc.contributor.authorPáez Leal, María Carolina
dc.contributor.authorAnaya C., Juan Manuel
dc.contributor.cvlacSerrano Diaz, Norma Cecilia [0000066613]spa
dc.contributor.cvlacPáez Leal, María Carolina [0000066656]spa
dc.contributor.cvlacDíaz Martínez, Luis Alfonso [0000066621]spa
dc.contributor.googlescholarSerrano Diaz, Norma Cecilia [iDn0AAAAAJ&hl=es&oi=ao]spa
dc.contributor.googlescholarPáez Leal, María Carolina [BAPR3-cAAAAJ]spa
dc.contributor.googlescholarDíaz Martínez, Luis Alfonso [ABarFDsAAAAJ]spa
dc.contributor.orcidSerrano Diaz, Norma Cecilia [0000-0003-3532-2002]spa
dc.contributor.orcidPáez Leal, María Carolina [0000-0002-0310-0125]spa
dc.contributor.orcidDíaz Martínez, Luis Alfonso [0000-0002-4498-6639]spa
dc.contributor.researchgatePáez Leal, María Carolina [Maria_Paez-Leal]spa
dc.contributor.scopusSerrano Diaz, Norma Cecilia [7003706613]spa
dc.contributor.scopusPáez Leal, María Carolina [12243485600]spa
dc.coverage.campusUNAB Campus Bucaramangaspa
dc.coverage.spatialBucaramanga (Santander, Colombia)spa
dc.coverage.temporal2005spa
dc.date.accessioned2023-11-20T15:56:17Z
dc.date.available2023-11-20T15:56:17Z
dc.date.issued2005
dc.description.abstractEl LES no es una enfermedad rara, pues su prevalencia en la población mundial fluctúa entre 2.9-206 casos x 100.000 habitantes, reportándose una mayor incidencia entre la población hispana y afroamericana, en cuyos grupos raciales suele presentar un curso más grave de la enfermedad. Este fenómeno ha sido atribuido por algunos expertos a factores socioeconómicos y ambientales, que colocan a países como Colombia como referentes para el estudio de esta entidad. Su etiología es aún desconocida, e involucra factores genéticos, hormonales y ambientales interactúan de una forma compleja en su génesis, representando el prototipo de las Enfermedades Complejas, donde la existencia de una predisposición genética en asociación con diferentes factores de riesgo medio ambientales, hacen que esa susceptibilidad genética se ponga de manifiesto y se desarrolle la enfermedad. Considerado el LES como una enfermedad compleja que cursa con disfunción endotelial en asociación con alteraciones en la biodisponibilidad del óxido nítrico, consideramos que el gen que codifica para la NOSe es un buen candidato que pudiera estar relacionado con el origen y desarrollo de la enfermedad, donde las variaciones genéticas representadas en polimorfismos del gen podrían comportarse como factor de riesgo independiente para el desarrollo de la misma. La importancia de determinar factores de riesgo genético asociados a la enfermedad permitiría en aquellas pacientes portadoras iniciar de manera temprana medidas terapéuticas que logren modificar el curso de la enfermedad.spa
dc.description.abstractenglishSLE is not a rare disease, since its prevalence in the world population fluctuates between 2.9-206 cases per 100,000 inhabitants, with a higher incidence reported among the Hispanic and African-American population, in whose racial groups usually presents a more severe course of the disease. This phenomenon has been attributed by some experts to socioeconomic and environmental factors, which place countries like Colombia as references for the study of this entity. Its etiology is still unknown, and it involves genetic, hormonal and environmental factors that interact in a complex way in its genesis, representing the prototype of Complex Diseases, where the existence of a genetic predisposition in association with different environmental risk factors, causes that genetic susceptibility becomes evident and the disease develops. Considering SLE as a complex disease that presents with endothelial dysfunction in association with alterations in the bioavailability of nitric oxide, we consider that the gene that codes for NOSe is a good candidate that could be related to the origin and development of the disease, where The genetic variations represented in gene polymorphisms could behave as an independent risk factor for its development. The importance of determining genetic risk factors associated with the disease would allow carrier patients to initiate therapeutic measures early that can modify the course of the disease.spa
dc.description.learningmodalityModalidad Presencialspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga - UNABspa
dc.identifier.reponamereponame:Repositorio Institucional UNABspa
dc.identifier.repourlrepourl:https://repository.unab.edu.cospa
dc.identifier.urihttp://hdl.handle.net/20.500.12749/22850
dc.language.isospaspa
dc.publisher.facultyFacultad Ciencias de la Saludspa
dc.publisher.grantorUniversidad Autónoma de Bucaramanga UNABspa
dc.relation.referencesPisetsky S. David: Sytemic Lupus Erythematosus, Epidemiology, Pathology and Pathogenesis. In Schumacher Ralph H Jr, Klippel H. John, Koopman y. William (Eds.) Primer on the Rheumatic Diseases 10th Edition. Georgia, Arthritis Foundation, 1993:100 -105.spa
dc.relation.referencesBetty P.Tsao: The Genetic of Human Lupus. In Wallace J. Daniel, M.D,, Hahn Hannahs Bevra, M.D. (Eds.). Dubois” Lupus Erythematosus 6th Edition. Philadelphia, Lippincot Williams and Wilkins. 2002: 97-119.spa
dc.relation.referencesRus Violeta, Hochberg C. Mark: The Epidemiology of Systemic Lupus Erythematosus. In Wallace J. Daniel, M.D., Hahn Hannahs Bevra, M.D. (Eds.). Dubois” Lupus Erythematosus. Philadelphia, Lippincot Williams and Wilkins. 2002: 66-68.spa
dc.relation.referencesMillard TP, McGregor JM, Molecular genetics of cutaneous lupus erythematosus. Exp Dermatol 2001;26:184-191.spa
dc.relation.referencesAnaya JM, Uribe M, Pérez A, Pinto LF, Molina JF, Londoño MC, Sanchez JF, Cadavid ME, Matute G. Clinical and immunological factors associated with lupus nephritis in northwestern Colombian patients. Biomédica (en prensa).spa
dc.relation.referencesOates JC, Ruiz P, Alexander A, Pippen AAM, Gilkeson GS. Effect of late modulation of nitric oxide production on murine lupus. Clin Immunol Immunopathol 1997; 83:86-92.spa
dc.relation.referencesBelmont HM, Levartovshy D, Goel A et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:1810-6.spa
dc.relation.referencesGilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri M. Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatology 1999;26:318-24.spa
dc.relation.referencesHo CY, Wong CK, Li EK, Tam LS, Lam CWK. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology 2003;42:117—122.spa
dc.relation.referencesVyse T.J., Kotzin B.L., 1998 Genetic Susceptibility to Systemic Lupus Erythematosus. Annu.Rev. Inmunology 16: 261-292.spa
dc.relation.referencesCorrea PA, Molina JF, Pinto LF, Arcos-Burgos M, Anaya JM. TAP1 and TAP2 polymorphism in northwestern Colombian patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 363-365.spa
dc.relation.referencesCorrea PA, Rivera D, Arcos-Burgos M, Molina JF, Pinto LF, Anaya JM. Microsatellite analysis defines a susceptibility region to systemic lupus erythematosus close to TNF alpha locus. Ann Rheum Dis (en prensa).spa
dc.relation.referencesHanafy K.A., Krumenacker J.S., Murad F. NO, nitrotyrosine and cyclic GMP in signal transduction. Med. Sci. Monit. (2001) 7801-819.spa
dc.relation.referencesMayer , B., John, M., and Bo“hme, E. (1990) Purification of a calcium/calmodulin-dependent nitric oxide synthase from porcine cerebellum. Cofactor role of tetrahydrobiopterin. FEBS Lelt. 277, 215-219.spa
dc.relation.referencesForstermann U, Boissel JP, Kleinert H. Expressional control of th “constitutive” isoforms of nitric oxide synthase (NOS | and NOSIII). FASEB J 1998;12:773-90.spa
dc.relation.referencesGreen S.J., Meltzer M.S., Hibbs J.B. Jr., Nacy C.A. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J. Immunol. (1990) 144 278-283.spa
dc.relation.referencesPalmer R.M., Hickery M.S., Charles |.G., Moncada S., Bayliss M.T. Induction of nitric oxide synthase in human chondrocytes. Biochem. Biophys. Res. Commun. 1993;193: 398-405.spa
dc.relation.referencesDrapier J-C, Hibbs JB. DiVerentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J Immunol 1988;140:2829-38.spa
dc.relation.referencesVan * Hof RJ, Hocking L, Wright SH. Nitric oxide is a mediator of apoptosis in the rheumatoid joint Vallance P. Rheumatology 2000;39:1004-8.spa
dc.relation.referencesDrapier J-C, Hibbs JB. Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J Immunol 1988;140:2829-38.spa
dc.relation.referencesTamir S, Burney S, Tannenbaum SR. DNA damage by nitric oxide. Chem Res Toxicol 1996;9:821—7.spa
dc.relation.referencesBeckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-4,spa
dc.relation.referencesChung H.T., Pae H.O., Choi B.M., Billiar T.R., Kim Y.M. Nitric oxide as a bioregulator of apoptosis. Biochem. Biophys. Res. Commun. (2001) 282 1075-1079.spa
dc.relation.referencesMerryman PF, Clancy RM, He XY, Abramson SB. Modulation of human T cell responses by nitric oxide and its derivative, S-nitrosoglutathione. Arthritis Rheum 1993;36:1414-22. 1992;51:1219-22.spa
dc.relation.referencesBelenky SN, Robbins RA, Rubinstein |. Nitric oxide synthase inhibitors attenuate human monocyte chemo- taxis in vitro. J Leukocyte Biol 1993;53:498-503.spa
dc.relation.referencesKubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651-5.spa
dc.relation.referencesKubes P, Kanwar S, Niu XF, Gaboury JP. Nitric oxide synthesis inhibition induces leukocyte adhesion via superoxide and mast cells. FASEB J 1993;7:1293-9.spa
dc.relation.referencesStadler J, Harbrecht BG, Di SilvioMet al. Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by rat kupVer cells. J Leukocyte Biol 1993;53:165- 72. 63-8.spa
dc.relation.referencesHogaboam CM, Befus AD, Wallace JL. Modulation of mast cell reactivity by IL-1-beta. Divergent effects on nitrite oxide and platelet-activating factor release. J Immunol 1993,151:3767—74.spa
dc.relation.referencesSalvemini D, Masini E, Pistelli A, Mannaioni PF, Vane y. Nitric oxide: a regulatory mediator of mast cell reactivity. J Cardiovasc Pharmacol 1991; 17(suppl. 3):S258-64.spa
dc.relation.referencesMiller MJS, Clark DA. Nitric oxide synthase inhibition can initiate or prevent gut inflammation: role of enzyme source. Agents Actions 1994;41:C231-2.spa
dc.relation.referencesWeinberg JB, Granger DL, Pisetsky DS et al. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL- Ipr/Ipr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J Exp Med 1994;179:651-60.spa
dc.relation.referencesWest SG. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994;20:129-58.spa
dc.relation.referencesBrundin L, Svenungsson E, Morcos E, Andersson M, Olsson T, Lundberg l, et al. Central nervous system nitric oxide formation in cerebral systemic lupus erythematosus. Ann Neurol 1998;44:704-6.spa
dc.relation.referencesSvenungsson E, Andersson M, Brundin L et al. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus Erythematosus. Ann Rheum Dis 2001;60:372-379).spa
dc.relation.referencesWigand R, Meyer J, Busse R et al. Increased serum N*-hydroxy-L-Arginina (L-NHA) in patients with rheumatoid arthritis and systemic lupus erythematousus as an index of an increased nitric oxide synthase activity. Annals of the Rheumatic Diseases 1997;56:330-2.spa
dc.relation.referencesLopez-Nevot MA, Ramal L, Jimenez-Alonso J, Martin J. The inducible nitric oxide synthase promoter polymorphism does not confer susceptibility to systemic lupus erythematosus. Rheumatology (Oxford) 2003 Jan;42(1):113-6.spa
dc.relation.referencesNakayama M, Yasue H, Toshimura M, et al. T”%C mutation in the 5”-flanking region of the endothelial nitric oxide synthase gene is associated with coronay spasm. Circulation 1999;99:2864-70.spa
dc.relation.referencesNakayama M, Yasue H, Toshimura M, et al. T"%C mutation in the 5“-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis. Am J Cardiol 2000;86:628-34.spa
dc.relation.referencesPoirier O Mao C, Mallet C, et al. Polymorphisms of the endothelial nitric oxide synthase gene no consistent association with myocardial infarction in the ECTIM study. Eur J Clin Investi 1999:29:284-90.spa
dc.relation.referencesSim AS, Wang y, Wilcken D, et al. Mspl polymorphism in the promoter of the human endothelial constitutive NO synthase gene in an Australian Caucasian population. Mol Genet Metab 1998;65:62.spa
dc.relation.referencesHingorani AD, Liang CF, Fatibene J, et al. A common variant of the endothelial nitric oxide synthase (Glu298Asp) is a major risk factor for coronary artery disease in the UK. Circulation 1999;100:1515-20.spa
dc.relation.referencesYoshimura M. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 1998;103:65-69.spa
dc.relation.referencesMiyamoto Y, Saito Y, Kajiyama N, et al. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 1998;32:3-8.spa
dc.relation.referencesShoji M et al. Positive association of endothelial nitric oxide synthase gene polymorphism with hypertension in northern Japan. Life Sci 2000;66:2557-62.spa
dc.relation.referencesShimasaki Y, et al. Association of the missense Glu298Asp variant of the nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol 1999;31:1506-10.spa
dc.relation.referencesMcNamara DM, et al. The Asp298 variant of endothelial nitric oxide synthase (eNOS) improves survival in patients with heart failure. Circulation 1999;100:1507.spa
dc.relation.referencesYoshimura T, Yoshimura M, Tabata A, et al. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with severe preeclampsia. J Soc Gynecol Invest 2000;7:238-41.spa
dc.relation.referencesTanus-Santos JE, Desai M, Flockhart D. Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 2001;11:719-25.spa
dc.relation.referencesTeasuro M, Thompson WC, Rogliani P et al. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 2000 97;2832-35spa
dc.relation.referencesSavvidou MD, Wallance PJ, Nicolaides KH, Hingorani A. Endothelial nitric oxide synthase gene polymorphism and maternal vascular adaptation to pregnancy. Hypertension 2001;38:1289-93spa
dc.relation.referencesTan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rhothfield NF,et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271- 77.spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.rights.localAbierto (Texto Completo)spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.subject.keywordsComplex diseasesspa
dc.subject.keywordsGeneticsspa
dc.subject.keywordsLupusspa
dc.subject.keywordsSystemic lupus erythematosusspa
dc.subject.keywordsBiological developmentspa
dc.subject.keywordsPolymorphismspa
dc.subject.keywordsPathophysiologyspa
dc.subject.lembLupus eritematoso sistémicospa
dc.subject.lembDesarrollo biológicospa
dc.subject.lembPolimorfismospa
dc.subject.lembFisiopatologíaspa
dc.subject.proposalEnfermedades complejasspa
dc.subject.proposalGenéticaspa
dc.subject.proposalLupusspa
dc.titleEstudio de polimorfismos de la Óxido Nítrico Sintasa Endotelial (NOSE) en pacientes con lupus eritematoso sistémicospa
dc.title.translatedStudy of polymorphisms of Endothelial Nitric Oxide Synthase (NOSe) in patients with systemic lupus erythematosusspa
dc.typeResearch reporteng
dc.type.coarhttp://purl.org/coar/resource_type/c_18ws
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.driverinfo:eu-repo/semantics/workingPaperspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localInforme de investigaciónspa
dc.type.redcolhttp://purl.org/redcol/resource_type/IFIspa

Archivos

Bloque original

Mostrando 1 - 2 de 2
Miniatura
Nombre:
2005_Informe de Investigación_Serrano_Díaz_Norma_Cecilia.pdf
Tamaño:
11.37 MB
Formato:
Adobe Portable Document Format
Descripción:
Informe de Investigación
Descargar
Miniatura
Nombre:
2005_Liencia_Serrano_Díaz_Norma_Cecilia.pdf
Tamaño:
2.49 MB
Formato:
Adobe Portable Document Format
Descripción:
Licencia
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
829 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Informes de investigación